NASDAQ:EPZM - Epizyme Stock Price, Forecast & News

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme Inc (NASDAQ:EPZM) posted its earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.11. The biopharmaceutical company earned $5.72 million during the quarter, compared to analyst estimates of $5.50 million. Epizyme had a negative net margin of 468.53% and a negative return on equity of 49.38%. View Epizyme's Earnings History.

Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Epizyme.

9 brokers have issued 12 month price targets for Epizyme's stock. Their forecasts range from $18.00 to $36.00. On average, they expect Epizyme's share price to reach $27.14 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price. View Analyst Price Targets for Epizyme.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Media coverage about EPZM stock has been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Epizyme earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Epizyme.

Epizyme saw a increase in short interest in January. As of January 15th, there was short interest totalling 8,780,000 shares, an increase of 9.5% from the December 31st total of 8,020,000 shares. Based on an average daily volume of 919,900 shares, the short-interest ratio is presently 9.5 days. Approximately 11.5% of the shares of the company are short sold. View Epizyme's Current Options Chain.

Some companies that are related to Epizyme include Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT) and Arrowhead Pharmaceuticals (ARWR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Amarin (AMRN), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), TG Therapeutics (TGTX), Verastem (VSTM), Crispr Therapeutics (CRSP), Exelixis (EXEL) and Gilead Sciences (GILD).

Epizyme's stock is owned by many different of retail and institutional investors. Top institutional investors include Palo Alto Investors LP (6.75%), Victory Capital Management Inc. (2.91%), Victory Capital Management Inc. (2.73%), State Street Corp (2.71%), FMR LLC (2.45%) and Loomis Sayles & Co. L P (1.76%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Institutional Ownership Trends for Epizyme.

EPZM stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, FMR LLC, State Street Corp, Palo Alto Investors LP, UBS Group AG, Rafferty Asset Management LLC, Goldman Sachs Group Inc. and Citigroup Inc.. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Insider Buying and Selling for Epizyme.

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., State of New Jersey Common Pension Fund D, Candriam Luxembourg S.C.A., Delta Investment Management LLC, EAM Investors LLC, First Trust Advisors LP and Bank of New York Mellon Corp. View Insider Buying and Selling for Epizyme.

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EPZM stock can currently be purchased for approximately $24.26.

Epizyme has a market capitalization of $2.21 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

The official website for Epizyme is http://www.epizyme.com/.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]